GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (STU:LSRM) » Definitions » YoY EBITDA Growth

CEL-SCI (STU:LSRM) YoY EBITDA Growth : 30.52% (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CEL-SCI YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. CEL-SCI's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 30.52%.

CEL-SCI's EBITDA per Share for the three months ended in Mar. 2024 was €-0.11.

CEL-SCI YoY EBITDA Growth Historical Data

The historical data trend for CEL-SCI's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI YoY EBITDA Growth Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.40 -8.89 -10.24 -7.98 21.91

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.44 11.76 29.35 28.77 30.52

CEL-SCI YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

CEL-SCI's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (A: Sep. 2023 )
=(EBITDA per Share (A: Sep. 2023 )-EBITDA per Share (A: Sep. 2022 ))/ | EBITDA per Share (A: Sep. 2022 ) |
=(-0.581--0.744)/ | -0.744 |
=21.91 %

CEL-SCI's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.107--0.154)/ | -0.154 |
=30.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of CEL-SCI's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI (STU:LSRM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (STU:LSRM) » Definitions » YoY EBITDA Growth
Comparable Companies
CRIS CLGN VTVT LTRN MNOV AVRO CKPT RLYB IKNA INTS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CVM:USA LSRM:Germany
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
Website
https://www.cel-sci.com
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI (STU:LSRM) Headlines

No Headlines